| 0.3224 -0.021 (-6.06%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.44 | 1-year : | 0.52 |
| Resists | First : | 0.38 | Second : | 0.44 |
| Pivot price | 0.34  |
|||
| Supports | First : | 0.28 | Second : | 0.22 |
| MAs | MA(5) : | 0.34 |
MA(20) : | 0.33 |
| MA(100) : | 0.39 |
MA(250) : | 0.61 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 68.4 |
D(3) : | 74.8 |
| RSI | RSI(14): 45.5 |
|||
| 52-week | High : | 1.44 | Low : | 0.22 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SILO ] has closed above bottom band by 22.7%. Bollinger Bands are 19.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.34 - 0.35 | 0.35 - 0.35 |
| Low: | 0.29 - 0.29 | 0.29 - 0.29 |
| Close: | 0.32 - 0.32 | 0.32 - 0.33 |
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Tue, 24 Feb 2026
Silo Pharma Announces $1 Mln Share Buyback Program; Stock Up - Nasdaq
Mon, 23 Feb 2026
Silo Pharma authorizes $1 million stock buyback program - Investing.com
Mon, 23 Feb 2026
Silo Pharma Announces $1 Million Stock Repurchase Program - TipRanks
Mon, 23 Feb 2026
Silo Pharma stock surges on $1M share buyback program - Investing.com
Mon, 23 Feb 2026
Silo Pharma Announces Share Buyback Program - GlobeNewswire
Mon, 23 Feb 2026
Biotech Silo Pharma approves $1M plan to buy back its own stock - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 1.288e+007 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 518 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.3e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 388.1 % |
| Return on Equity (ttm) | -44.4 % |
| Qtrly Rev. Growth | 72100 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -141.17 |
| EBITDA (p.s.) | 77114.8 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.4 |
| Dividend | 0 |
| Forward Dividend | 490730 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|